Estimating the marginal cost of a life year in Sweden’s public healthcare sector

Abstract

Although cost-effectiveness analysis has a long tradition of supporting healthcare decision-making in Sweden, there are no clear criteria for when an intervention is considered too expensive. In particular, the opportunity cost of healthcare resource use in terms of health forgone has not been investigated empirically. In this work, we therefore seek to estimate the marginal cost of a life year in Sweden’s public healthcare sector using time series and panel data at the national and regional levels, respectively. We find that estimation using time series is unfeasible due to reversed causality. However, through panel instrumental variable estimation we are able to derive a marginal cost per life year of about SEK 370,000 (EUR 39,000). Although this estimate is in line with emerging evidence from other healthcare systems, it is associated with uncertainty, primarily due to the inherent difficulties of causal inference using aggregate observational data. The implications of these difficulties and related methodological issues are discussed. Electronic supplementary material The online version of this article (10.1007/s10198-019-01039-0) contains supplementary material, which is available to authorized users.

Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden

“…These preliminary results should be interpreted with caution as we have not applied a lifetime perspective on survival and costs. Our findings, however, indicate that empagliflozin is cost-effective, as the estimated cost per QALY is well below both commonly applied threshold values [14] and the marginal productivity of the healthcare sector [15].…”

Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries

“…These are typically reported as a cost per quality-adjusted life year (QALY) gained or disability-adjusted life years (DALY) averted. [3][4][5][6][7][8][9][10][11][12][13] Comparing the additional cost per QALY gained or DALY averted by an intervention with an estimate of cost per QALY gained or DALY averted that reflects health opportunity costs enables a binary assessment of whether the intervention produces health at a better (worse) rate than interventions already funded by the healthcare system (HCS)-that is, is below (above) the estimate of cost per QALY gained or DALY averted that reflects health opportunity costs. However, binary assessments such as these obscure valuable information about the scale of the net benefits (or losses) associated with providing or developing an intervention, and other local context-specific important criteria of affordability, budget impact, fairness and feasibility.…”

Mutually Exclusive Interventions in the Cost-Effectiveness Bookshelf

“…That it has proved difficult to identify displaced interventions 7–9 would seem to support such an interpretation. Recent empirical work attempting to estimate the marginal effect of health care spending 10–13 can be seen as a less literal way of trying to identify the marginal intervention. 14…”